US equities
|
MU
$1,026.99
▼-0.85%
NVDA
$229.76
▼-0.31%
SPCX
$161.59
▲+0.64%
TSLA
$383.90
▲+2.37%
AAPL
$337.15
▼-0.96%
META
$719.38
▼-0.21%
SNDK
$1,586.52
▼-1.43%
AMD
$609.66
▼-1.78%
MU
$1,026.99
▼-0.85%
NVDA
$229.76
▼-0.31%
SPCX
$161.59
▲+0.64%
TSLA
$383.90
▲+2.37%
AAPL
$337.15
▼-0.96%
META
$719.38
▼-0.21%
SNDK
$1,586.52
▼-1.43%
AMD
$609.66
▼-1.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
RenovoRx, Inc. - Common Stock
(NQ:
RNXT
)
1.275
-0.055 (-4.14%)
Delayed Quote
Updated: 3:30 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about RenovoRx, Inc. - Common Stock
< Previous
1
2
3
4
Next >
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today
June 23, 2026
From
iAccess Alpha
Via
ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026
June 18, 2026
From
iAccess Alpha
Via
ACCESS Newswire
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
January 08, 2026
From
Equity Insider
Via
GlobeNewswire
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
December 08, 2025
Via
ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
December 01, 2025
Via
ACCESS Newswire
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025
September 16, 2025
Via
ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025
September 09, 2025
Via
ACCESS Newswire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
August 20, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
August 14, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
July 28, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
July 14, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
May 15, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
May 14, 2025
From
RenovoRx, Inc.
Via
Business Wire
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
May 06, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
May 01, 2025
From
RenovoRx, Inc.
Via
Business Wire
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
April 29, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
April 16, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
April 04, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
April 01, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
March 28, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
March 26, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
March 20, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
March 19, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
February 26, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
February 13, 2025
From
RenovoRx, Inc
Via
Business Wire
BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering
February 12, 2025
Via
Investor Brand Network
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
February 11, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
February 06, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Proposed Public Offering
February 06, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
January 27, 2025
From
RenovoRx, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
